Hua Li

Hua Li


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Developmental Biology
Verified
Journal Article
Closed access
RMRebecca McLennan
Rebecca McLennan
LSLinus J. Schumacher
Linus J. Schumacher
JMJason A. Morrison
Jason A. Morrison
JTJessica M. Teddy
Jessica M. Teddy
DRDennis A. Ridenour
Dennis A. Ridenour
PKPaul M. Kulesa
Paul M. Kulesa

1 December 2023 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
FZFeng Zhu
Feng Zhu
PZPengpeng Zhang
Pengpeng Zhang
YLYing Liu
Ying Liu
CBChongchan Bao
Chongchan Bao
DQDong Qian
Dong Qian
TYTing Yu
Ting Yu
Background: Alterations in gut microbiota composition and function have been linked to the development and progression of thyroid cancer (TC). However, the exact nature of the causal relationship between them remains uncertain.Methods: A bidirectional two-sample Mendelian randomization (TSMR) analysis was conducted to assess the causal connection between gut microbiota (18,340 individuals) and TC (6,699 cases combined with 1,613,655 controls) using data from a genome-wide association study (GWAS). The primary analysis used the inverse-variance weighted (IVW) method to estimate the causal effect, with supplementary approaches including the weighted median, weighted mode, simple mode, and MR-Egger. Heterogeneity and pleiotropy were assessed using the Cochrane Q test, MR-Egger intercept test, and MR-PRESSO global test. A reverse TSMR analysis was performed to explore reverse causality.Results: This study identified seven microbial taxa with significant associations with TC. Specifically, the genus Butyrivibrio (OR: 1.127, 95% CI: 1.008-1.260, p = 0.036), Fusicatenibacter (OR: 1.313, 95% CI: 1.066-1.618, p = 0.011), Oscillospira (OR: 1.240, 95% CI: 1.001-1.536, p = 0.049), Ruminococcus2 (OR: 1.408, 95% CI: 1.158-1.711, p < 0.001), Terrisporobacter (OR: 1.241, 95% CI: 1.018-1.513, p = 0.032) were identified as risk factors for TC, while The genus Olsenella (OR: 0.882, 95% CI: 0.787-0.989, p = 0.031) and Ruminococcaceae UCG004 (OR: 0.719, 95% CI: 0.566-0.914, p = 0.007) were associated with reduced TC risk. The reverse MR analysis found no evidence of reverse causality and suggested that TC may lead to increased levels of the genus Holdemanella (β: 0.053, 95% CI: 0.012~0.094, p = 0.011) and decreased levels of the order Bacillales (β: -0.075, 95% CI: -0.143~-0.006, p = 0.033). No significant bias, heterogeneity, or pleiotropy was detected in this study.Conclusion: This study suggests a potential causal relationship between gut microbiota and TC, providing new insights into the role of gut microbiota in TC. Further research is needed to explore the underlying biological mechanisms.

24 January 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
LJLihe Jiang
Lihe Jiang
PWPeili Wang
Peili Wang
YHYixuan Hou
Yixuan Hou
JCJingying Chen
Jingying Chen
HLHua Li
Hua Li
Background: The convergence of macrophage-targeted strategies with immune checkpoint blockade therapies defines a pivotal avenue in contemporary tumor therapy. Identifying robust genetic regulators in this context is imperative.Methods: This study elucidates IFI30's role in enhancing Major Histocompatibility Complex II (MHC-II) restriction antigen processing. Despite its recognition in cancer immunotherapy, IFI30 remains a nascent focus. Our approach involves a multi-omics analysis of IFI30 tumor immunological profile in the macrophage-mediated Tumor Microenvironment (TME), spanning various cancers and bolstered by rigorous co-culture laboratory work.Results: IFI30 predominantly localizes in monocyte/macrophage populations, correlating strongly with immune cell infiltration. Substantiated by single-cell analysis, IFI30 exhibits significant functional enrichment in immune-related pathways. Co-expression with immune-related genes, including MHC elements and immune checkpoints, further validates its relevance.Conclusion: Our study positions IFI30 as a promising immunotherapeutic target. Pan-cancer analyses and glioblastoma multiforme (GBM) investigations collectively underscore IFI30's potential as a TME modulator, particularly in its interaction with M2-macrophages. IFI30 emerges as a prospective intervention point in the immunotherapeutic landscape.

19 May 2025 in Frontiers in Bioscience-Landmark
Verified
Journal Article
Open access
HLHua Li
Hua Li
LXLihua Xu
Lihua Xu
JCJingying Chen
Jingying Chen
HHHuijuan Huang
Huijuan Huang
FLFeiteng Liang
Feiteng Liang
JGJunyu Guo
Junyu Guo
Background: The excessive formation of neutrophil extracellular traps (NETs) is involved in delayed wound healing under diabetic conditions. However, potential therapeutic agents remain underexplored. Our present study aimed to explore the effects of Ro 106-9920, a specific nuclear factor kappa B (NF-κB) inhibitor, on diabetic wound healing and to elucidate the underlying mechanisms. Methods: A diabetic mouse model was established, and full-thickness wounds were created. Ro 106-9920 was administered, and wound healing was monitored. Protein levels of NET markers and nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome components were assessed via western blotting and histological analysis. Functional assays were conducted to evaluate the effect of NETs on fibroblasts, endothelial cells, and keratinocytes using conditioned media (CM) from a phorbol 12-myristate 13-acetate (PMA)-treated neutrophil-macrophage coculture model (NET-CM). CM collected from the coculture model after Ro 106-9920 treatment ((NET+Ro 106-9920)-CM) was used to determine its therapeutic potential. Results: NET formation and NLRP3 inflammasome activation were significantly elevated in wound tissues of diabetic mice from day 7 (p < 0.001). Similar results were observed in PMA-treated neutrophils and macrophages (p < 0.001). The viability and migration of endothelial cells, fibroblasts, and keratinocytes, as well as the angiogenic potential of endothelial cells, were significantly impaired by NET-CM treatment (all p < 0.001), whereas Ro 106-9920 effectively attenuated these alterations (NET-CM vs. (NET+Ro 106-9920)-CM, cell viability, p < 0.001; cell migration, p < 0.01; tube formation, p < 0.001). In vivo, Ro 106-9920 treatment inhibited NET formation, as evidenced by the decreased citrullinated histone H3 (CitH3) and peptidyl arginine deiminase 4 (PAD4) expression (p < 0.05). This was followed by a decrease in NLRP3 inflammasome activation (p < 0.05), an increase in angiogenesis in wound tissues (p < 0.001), and improved wound healing (p < 0.001) compared with those in Ro 106-9920-untreated mice. Conclusions: Ro 106-9920 enhances diabetic wound healing by suppressing NET formation and inhibiting NLRP3 inflammasome activation, providing a novel therapeutic choice for improving chronic wound healing in patients with diabetes.

6 March 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
GNGaofeng Ni
Gaofeng Ni
XLXinhan Li
Xinhan Li
WNWenyang Nie
Wenyang Nie
ZZZhenzhen Zhao
Zhenzhen Zhao
HLHua Li
Hua Li
HZHongyan Zang
Hongyan Zang
Background: Breast Cancer (BC) ranks among the top three most prevalent cancers globally and stands as the principal contributor to cancer-related fatalities among women. In spite of the substantial occurrence rate of BC, the early stage of this disease is generally regarded as curable. However, intra-tumor heterogeneity presents a formidable obstacle to the success of effective treatment. Method: In this research, single cell RNA sequencing was utilized to dissect the tumor microenvironment within BC. Slingshot, CytoTRACE and Monocle 2 were applied to illustrate the differentiation process of each subpopulation in the pseudotime sequence. To comprehensively comprehend the tumor cells (TCs) in BC, an analysis of upstream transcription factors was carried out via pySCENIC, while downstream pathway enrichment was conducted through KEGG, GO and GSEA. The prognosis model was established based on the bulk data obtained from TCGA and GEO databases. Knock-down experiments were also implemented to explore the function of the transcription factor CEBPD in the TCs. Results: Our in-depth analysis identified eight principal cell types. Notably, TCs were predominantly found within epithelial cells. The classification of TCs further uncovered five unique subpopulations, with one subpopulation characterized by high UGDH expression. This subpopulation was shown to possess distinct metabolic features in metabolism-related investigations. The intricate communication modalities among different cell types were effectively demonstrated by means of CellChat. Additionally, a crucial transcription factor, CEBPD , was identified, which demonstrated a pronounced propensity towards tumors and harbored potential tumor-advancing characteristics. Its role in promoting cancer was subsequently verified through in vitro knock-down experiments. Moreover, a prognostic model was also developed, and a risk score was established based on the genes incorporated in the model. Through comparing the prognoses of different UTRS levels, it was determined that the group with a high UTRS had a less favorable prognosis. Conclusion: These outcomes contributed to the elucidation of the complex interrelationships within the BC tumor microenvironment. By specifically targeting certain subpopulations of TCs, novel treatment strategies could potentially be devised. This study shed light on the direction that future research in BC should take, furnishing valuable information that can be utilized to enhance treatment regimens.

10 November 2023 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
HLHua Li
Hua Li
LPLujuan Pan
Lujuan Pan
JGJunyu Guo
Junyu Guo
JLJianLe Lao
JianLe Lao
MWMingwei Wei
Mingwei Wei
FHFuda Huang
Fuda Huang
Several studies have shown significant involvement of tumor-associated macrophages (TAMs) in the tumor microenvironment and cancer progression. However, no data on reliable TAM-related biomarkers are available for predicting the prognosis of patients with colorectal cancer (CRC). We analyzed the clinical data and gene expression profiles of patients with CRC from databases. The single-cell transcriptomic data was applied to identify M2-like TAM-related differentially expressed genes. Univariate Cox and least absolute shrinkage and selection operator regression analyses were used to determine the prognostic signature genes. Then, seven key genes were screened to develop the prognostic signature. In the training and external validation cohorts, the overall survival (OS) of patients in the high-risk group was significantly shorter compared to the low-risk group. Consequently, we created a nomogram that could accurately and reliably predict the prognosis of patient with CRC. A significant correlation was observed between the patient’s prognosis, clinical features, sensitivity to anticancer drugs, TME, and risk scores. Moreover, risk score was strongly related to the response to immunotherapy in patients from GSE91061, GSE78220, and GSE60331 cohorts. Finally, high expression of HSPA1A, SERPINA1, CXCL1, and low expression of DNASE1L3 were found in human CRC tissue and normal tissue by using qRT-PCR. In conclusion, the M2-like TAM-related prognostic signature could predict the survival, prognosis, and response of patients with CRC to immunotherapy, which sheds light on the role of TAMs in CRCs and enhances our understanding of TAMs.